Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia

References

• Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005; 365: 785–99
   PubMed Web of Science ®Google Scholar
• Redman CW, Sargent IL. Latest advances in understanding pre-eclampsia. Science. 2005; 308: 1592–4
   PubMed Web of Science ®Google Scholar
• Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of pre-eclampsia. N Engl J Med. 2004; 350: 672–83
   PubMed Web of Science ®Google Scholar
• Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. CPEP study group. Soluble endoglin and other circulating antiangiogenic factors in pre-eclampsia. N Engl J Med. 2006; 355: 992–1005
   PubMed Web of Science ®Google Scholar
• Venkatesha S, Toporsian M, Lami C, Hanai J, Mammoto T, Kim YM, et al. Soluble endoglin contributes to the pathogenesis of pre-eclampsia. Nat Med. 2006; 12: 642–9
   PubMed Web of Science ®Google Scholar
• Toporsian M, Gros R, Kabir MG, Vera S, Govindaraju K, Eidelman DH, et al. A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res. 2005; 96: 684–92
   PubMed Web of Science ®Google Scholar
• Shibuya M, Yamaguchi S, Yamane A, Ykeda T, Tojo A, Matsushime H, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene. 1990; 5: 519–24
   PubMed Web of Science ®Google Scholar
• Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in pre-eclampsia. J Clin Invest. 2003; 111: 649–58
   PubMed Web of Science ®Google Scholar
• Tsatsaris V, Goffin F, Munaut C, Brichant JF, Pignon MR, Noel A, et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: Pathophysiological consequences. J Clin Endocrinol Metab. 2003; 88: 5555–63
   PubMed Web of Science ®Google Scholar
• Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem. 2003; 278: 12605–8
   PubMed Web of Science ®Google Scholar
• Persico MG, Vincenti V, DiPalma T. Structure, expression and receptor-binding properties of placenta growth factor (PlGF). Vascular growth factors and angiogenesis, L. Claesson-Welsh. Springer-Verlag, Berlin 1999; 31–40
   Google Scholar
• Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med. 2003; 9: 936–43
   PubMed Web of Science ®Google Scholar
• Odorisio T, Schietroma C, Zaccaria ML, Cianfarani F, Tiveron C, Tatangelo L, et al. Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability. J Cell Sci. 2002; 115: 2559–67
   PubMed Web of Science ®Google Scholar
• Levine RJ, Thadhani R, Qian C, Lam C, Lim KH, Yu KF, et al. Urinary placental growth factor and risk of pre-eclampsia. JAMA. 2005; 293: 77–85
   PubMed Web of Science ®Google Scholar
• Schwärzler P, Bland JM, Holden D, Campbell S, Ville Y. Sex-specific antenatal reference growth charts for uncomplicated singleton pregnancy at 15–40 weeks of gestation. Ultrasound Obstet Gynecol. 2004; 23: 23–9
   PubMed Web of Science ®Google Scholar
• Moore Simas TA, Crawford SL, Solitro MJ, Frost SC, Meyer BA, Maynard SE. Angiogenic factors for the prediction of pre-eclampsia in high-risk women. Am J Obstet Gynecol. 2007; 197: 294.e1–244e.8
   PubMed Web of Science ®Google Scholar
• Livingston JC, Chin R, Haddad B, McKinney ET, Ahokas R, Sibai BM. Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia. Am J Obstet Gynecol. 2000; 183: 1554–7
   PubMed Web of Science ®Google Scholar
• Lam C, Lim K, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of pre-eclampsia. Hypertension. 2005; 46: 1077–85
   PubMed Web of Science ®Google Scholar
• Otrock ZK, Makarem JA, Shamseddine AI. Vascular endothelial growth factor family of ligands and receptors: Review. Blood Cells Mol Dis. 2007; 38: 258–68
   PubMed Web of Science ®Google Scholar
• Ohkuchi A, Hirashima C, Matsubara S, Suzuki H, Takahashi K, Arai F, et al. Alterations in placental growth factor levels before and after the onset of pre-eclampsia are more pronounced in women with early onset severe pre-eclampsia. Hypertens Res. 2007; 30: 151–9
   PubMed Web of Science ®Google Scholar
• Wikström AK, Larsson A, Eriksson UJ, Nash P, Nordén-Lindeberg S, Olovsson M. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset pre-eclampsia. Obstet Gynecol. 2007; 109: 1368–74
   PubMed Web of Science ®Google Scholar
• D'Anna R, Baviera G, Corrado F, Giordano D, De Vivo A, Nicocia G, et al. Adiponectin and insulin resistance in early- and late-onset pre-eclampsia. BJOG. 2006; 113: 1264–9
   PubMed Web of Science ®Google Scholar
• Makris A, Thornton C, Thompson J, Thomson S, Martin R, Ogle R, et al. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int. 2007; 71: 977–84
   PubMed Web of Science ®Google Scholar
• Hisashi Masuyama H, Nakatsukasa H, Takamoto N, Hiramatsu Y. Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in pre-eclampsia. J Clin Endocrinol Metab. 2007; 92: 2672–9
   PubMed Web of Science ®Google Scholar
• Unal ER, Robinson CJ, Johnson DD, Chang EY. Second-trimester angiogenic factors as biomarkers for future-onset pre-eclampsia. Am J Obstet Gynecol. 2007; 197: 211.e1–211.e4
   PubMed Web of Science ®Google Scholar